Biomarkers for malignant peripheral nerve sheath tumours

Expert Opinion on Medical Diagnostics

Volumn 2, Issue 7, 2008, Pages 801-811

  Reuss, D E ^a   von Deimling, Andreas ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biomarkers; Differential diagnosis; Malignant peripheral nerve sheath tumour; Neurofibroma

Indexed keywords

CD57 ANTIGEN; COLLAGENASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE 14; MYELIN BASIC PROTEIN; NESTIN; NEUROFIBROMIN; ONCOLYTIC HERPES VIRUS; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P16; PROTEIN P27; PROTEIN P53; PROTEIN S 100; RAS PROTEIN; RETINOBLASTOMA PROTEIN; STEROID HORMONE; SURVIVIN; TENASCIN; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CYTOGENETICS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE MARKER; DRUG MECHANISM; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MONOTHERAPY; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; NONHUMAN; PATHOGENESIS; REVIEW;

EID: 77953462959     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2.7.801     Document Type: Review

References (86)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97-109
2. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91(10):1914-26
3. Hashimoto H, Daimaru Y, Takeshita S, et al. Prognostic significance of histologic parameters of soft tissue sarcomas. Cancer 1992;70(12):2816-22
4. Bader JL. Neurofibromatosis and cancer. Ann NY Acad Sci 1986;486:57-65
5. Huson SM, Hughes RAC. The neurofibromatoses: a pathogenetic and clinical overview. Edition. Chapman & Hall Medical, London; New York; 1994. p. xiii, 487, [484] p. of plates
6. Hagel C, Zils U, Peiper M, et al. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neuro Oncol 2007;82(2):187-92
7. Weiss SW, Goldblum JR, Enzinger FM. Enzinger and Weiss's soft tissue tumors. Edition. Mosby, St Louis; 2001. p. xiv, 1622
8. Fisher C, Carter RL, Ramachandra S, Thomas DM. Peripheral nerve sheath differentiation in malignant soft tissue tumours: an ultrastructural and immunohistochemical study. Histopathology 1992;20(2):115-25
9. Mertens F, Rydholm A, Bauer HF, et al. Cytogenetic findings in malignant peripheral nerve sheath tumors. Int J Cancer 1995;61(6):793-8
10. Mertens F, Dal Cin P, De Wever I, et al. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J Pathol 2000;190(1):31-8
11. Jhanwar SC, Chen Q, Li FP, et al. Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST). Cancer Genet Cytogenet 1994;78(2):138-44
12. Kobayashi C, Oda Y, Takahira T, et al. Chromosomal aberrations and microsatellite instability of malignant peripheral nerve sheath tumors: a study of 10 tumors from nine patients. Cancer Genet Cytogenet 2006;165(2):98-105
13. Rickert CH, Paulus W. Comparative genomic hybridization in central and peripheral nervous system tumors of childhood and adolescence. J Neuropathol Exp Neurol 2004;63(5):399-417
14. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 1993;3(2):122-6
15. Upadhyaya M, Han S, Consoli C, et al. Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. Hum Mutat 2004;23(2):134-46
16. Perry A, Roth KA, Banerjee R, et al. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol 2001;159(1):57-61
17. Ballester R, Marchuk D, Boguski M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990;63(4):851-9
18. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 193;366(6456):643-54
19. Maertens O, Brems H, Vandesompele J, et al. Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum Mutat 206;27(10):1030-40
20. Serra E, Rosenbaum T, Winner U, et al. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet 2000;9(20):3055-64
21. Serra E, Ars E, Ravella A, et al. Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. Hum Genet 2001;108(5):416-29
22. Kluwe L, Friedrich R, Maumer VF. Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosomes Cancer 1999;24(3):283-5
23. Rutkowski JL, Wu K, Gutmann DH, et al. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet 2000;9(7):1059-66
24. Sherman LS, Atit R, Rosenbaum T, et al. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem 2000;275(39):30740-5
25. Legius E, Dierick H, Wu R, et al. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 1994;10(4):250-5
26. Menon AG, Anderson KM, Riccardi VM, et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA 1990;87(14):5435-9
27. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev 2002;2(8):594-604
28. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000;60(24):6788-93
29. Petrone F, Tabano S, Colombo F, et al. p15INK4b, p 14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res 2003;9(11):4132-8
30. Kourea HP, Orlow I, Scheithauer BW, et al. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol 1999;155(6):1855-60
31. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, et al. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inacuvation. Am J Pathol 1999;155(6):1879-84
32. Mawrin C, Kirches E, Boltze C, et al. Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch 2002;440(6):610-5
33. Declue JE, Heffelfinger S, Benvenuto G, et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 2000;105(9):1233-41
34. Holtkamp N, Okuducu AF, Mucha J, et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 2006;27(3):664-71
35. Lothe RA, Karhu R, Mandahl N, et al. Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghansen's neurofibromatosis. Cancer Res 1996;56(20):4778-81
36. Mechtersheimer G, Otano-Joos M, Ohl S, et al. Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization. Genes Chromosomes Cancer 1999;25(4):362-9
37. Schmidt H, Wurl P, Taubert H, et al. Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer 1999;25(3):205-11
38. Storlazzi CT, Brekke HR, Mandahl N, et al. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. J Pathol 2006;209(4):492-500
39. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396(6711):580-4
40. Giodini A, Kallio MJ, Wall NR, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002;62(9):2462-7
41. Skotheim RI, Kallioniemi A, Bjerkhagen B, et al. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol 2003;21(24):4586-91
42. Kellner U, Sehested M, Jensen PB, et al. Culprit and victim - DNA topoisomerase II. Lancet Oncol 2002;3(4):235-43
43. Coindre JM, Hostein I, Benhattar J, et al. Malignant peripheral nerve sheath tumors are t(X; 18)-negative sarcomas. Molecular analysis of 25 cases occurring in neurofibromatosis type 1 patients, using two different RT-PCR-based methods of detection. Mod Pathol 2002;15(6):589-92
44. Jacks T, Shih TS, Schmitt EM, et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994;7(3):353-61
45. Cichowski K, Shih TS, Schmitt E, et al. Mouse models of tumor development in neurofibromatosis type 1. Science (New York, NY) 1999;286(5447):2172-6
46. Zhu Y, Ghosh P, Charnay P, et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science (New York, NY) 2002;296(5569):920-2
47. Vogel KS, Klesse LJ, Velasco-Miguel S, et al. Mouse tumor model for neurofibromatosis type 1. Science (New York, NY) 1999;286(5447):2176-9
48. Stemmer-Rachamimov AO, Louis DN, Nielsen GP, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 2004;64(10):3718-24
49. Mahller YY, Vaikunth SS, Currier MA, et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenografr model. Mol Ther 2007;15(2):279-86
50. Perrin GQ, Li H, Fishbein L, et al. An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation. Lab Invest 2007;87(11):1092-102
51. Perry A, Kunz SN, Fuller CE, et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 2002;61(8):702-9
52. Johnson MD, Glick AD, Davis BW. Immunohistochemical evaluation of Leu-7, myelin basic-protein, S100-protein, glial-fibrillary acidic-protein, and LN3 immunoreactivity in nerve sheath tumors and sarcomas. Arch Pathol Lab Med 1988;112(2):155-60
53. Kawahara E, Oda Y, Ooi A, et al. Expression of glial fibrillary acidic protein (GFAP) in peripheral nerve sheath tumors. A comparative study of immunoreactivity of GFAP, vimentin, S-100 protein, and neurofilament in 38 schwannomas and 18 neurofibromas. Am J Surg Pathol 1988;12(2):115-20
54. Yasuda T, Sobue G, Ito T, et al. Human peripheral nerve sheath neoplasm: expression of Schwann cell-related markers and their relation to malignant transformation. Muscle Nerve 1991;14(9):812-9
55. Weiss SW, Langloss JM, Enzinger FM. Value of S-100 protein in the diagnosis of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors. Lab Invest 1983;49(3):299-308
56. Wick MR, Swanson PE, Scheithauer BW, Manivel JC. Malignant peripheral nerve sheath tumor. An immunohistochemical study of 62 cases. Am J Clin Pathol 1987;87(4):425-33
57. Fisher C, Schofield JB. S-100 protein positive synovial sarcoma. Histopathology 1991;19(4):375-77
58. Smith TA, Machen SK, Fisher C, Goldblum JR. Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from malignant peripheral nerve sheath tumor. Am J Clin Pathol 1999;112(5):641-8
59. Tohyama T, Lee VM, Rorke LB, et al. Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest 1992;66(3):303-13
60. Shimada S, Tsuzuki T, Kuroda M, et al. Nestin expression as a new marker in malignant peripheral nerve sheath tumors. Pathol Int 2007;57:60-7
61. Olsen SH, Thomas DG, Lucas DIL Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol 2006;19(5):659-68
62. Halling KC, Scheithauer BW, Halling AC, et al. p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am J Clin Pathol 1996;106(3):282-8
63. Kindblom LG, Ahlden M, Meis-Kindblom JM, Stenman G. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Virchows Arch 1995;427(1):19-26
64. Liapis H, Marley EF, Lin Y, Dehner LP. p53 and Ki-67 proliferating cell nuclear antigen in benign and malignant peripheral nerve sheath tumors in children. Pediatr Dev Pathol 1999;2(4):377-84
65. Kourea HP, Cordon-Cardo C, Dudas M, et al. Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol 1999;155(6):1885-91
66. Zhou H, Coffin CM, Perkins SL, et al. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. Am J Surg Pathol 2003;27(10):1337-45
67. Thanakit V, Shuangshoti S, Ruangvejvorachai P. Expression of CyclinDl, p27kp-1, and bcl-2 in plexiform neurofibroma with and without malignant transformation in neurofibromatosis type 1. J Med Assoc Thai 2006;89(Suppl 3):S53-7
68. Nabeshima K, Iwasaki H, Nishio J, et al. Expression of emmprin and matrix metalloproteinases (MMPs) in peripheral nerve sheath tumors: emmprin and membrane-type (MT) 1-MMP expressions are associated with malignant potential. Anticancer Res 2006;26(2B):1359-67
69. Holtkamp N, Atallah I, Okuducu AF, et al. MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia (New York, NY) 2007;9(8):671-7
70. Nagayama S, Katagiri T, Tsunoda T, et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 2002;62(20):5859-66
71. Nakayama R, Nemoto T, Takahashi H, et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibmus histiocytoma. Mod Pathol 2007;20(7):749-59
72. Francis P, Namlos HM, Muller C, et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007;8:73
73. Holtkamp N, Mautner VF, Friedrich RE, et al. Differentially expressed genes in neurofibrornatosis 1-associated neurofibrornas and malignant peripheral nerve sheath tumors. Acta Neuropathol 2004;107(2):159-68
74. Holtkamp N, Reuss DE, Atallah 1, et al. Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathol (Zurich, Switzerland) 2004;14(3):258-64
75. Levy P, Bieche I, Leroy K, et al. Molecular profiles of neurofibromatosis type 1 -associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis. Clin Cancer Res 2004; 10(10:3763-71
76. Castanon I, Baylies MK. A Twist in face: evolutionary comparison of Twist structure and function. Gene 2002;287(1-2):11-22
77. Miller SJ, Rangwala F, Williams J, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath rumor cell lines and tissues. Cancer Res 2006;66(5):2584-91
78. Karube K, Nabeshima K, Ishigum M, et al. cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours. J Clin Pathol 2006;59(2):160-5
79. Levy P, Ripoche H, Laurendeau I, et at. Microarray-based identification of tenascin C and tenascin XB, genes possibty involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res 2007;13(2 Pr 1)398-407
80. Casadei CP, Scheithauer BW, Hirose T, et al. Cellular schwannorna. A clinicopathologic, DNA flow cytometric, and proliferation marker study of 70 patients. Cancer 1995;75(5):1109-19
81. Muiir D, Neubauer D, Lim IT, et al. Turnorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol 2001;158(2):501-13
82. Klose A, Ahmadian MR, Schuelke M, et al. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Hum Mol Genet 1998;7(8):1261-8
83. Joseph NM, Mosher JT, Buchstaller J, et al. The loss of Nfi transiently promotes self-renewal bur not tumorigenesis by neural crest stern cells. Cancer Cell 2008;13(2):129-40
84. Wu J, Williams JP, Rizvi TA, et al. Plexiform. and derrnal neurofibrornas and piginentation are caused by Nfl loss in desert hedgehog-expressing cells. Cancer Cell 2008; 13(2):105-16
85. Subramanian S, Lui WO, Lee CH, et al. MicroRNA. expression signature of human sarcornas. Oncogene 2007;27:2015-26
86. Duffy MJ, O'Donovan N, Brennan Dj, et al. Survivin: a promising rumor biomaker. Cancer Lett 2007;249(1):49-60